Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2007

1.

Valproic acid in pregnancy: how much are we endangering the embryo and fetus?

Ornoy A.

Reprod Toxicol. 2009 Jul;28(1):1-10. doi: 10.1016/j.reprotox.2009.02.014. Epub 2009 Mar 13. Review.

PMID:
19490988
2.

Teratogenicity of sodium valproate.

Alsdorf R, Wyszynski DF.

Expert Opin Drug Saf. 2005 Mar;4(2):345-53. Review.

PMID:
15794725
3.
4.

Neuroteratogens in man: an overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy.

Ornoy A.

Reprod Toxicol. 2006 Aug;22(2):214-26. Epub 2006 Apr 18. Review.

PMID:
16621443
6.

Exencephaly and axial skeletal malformations induced by maternal administration of sodium valproate in the MF1 mouse.

Padmanabhan R, Hameed MS.

J Craniofac Genet Dev Biol. 1994 Jul-Sep;14(3):192-205.

PMID:
7852547
7.

Folic acid and pantothenic acid protection against valproic acid-induced neural tube defects in CD-1 mice.

Dawson JE, Raymond AM, Winn LM.

Toxicol Appl Pharmacol. 2006 Mar 1;211(2):124-32. Epub 2005 Aug 22.

PMID:
16112698
8.

Myo-inositol enhances teratogenicity of valproic acid in the mouse.

Massa V, Wlodarczyk B, Giavini E, Finnell RH.

Birth Defects Res A Clin Mol Teratol. 2006 Mar;76(3):200-4.

PMID:
16511884
9.

Hydroxamic acid and fluorinated derivatives of valproic acid: anticonvulsant activity, neurotoxicity and teratogenicity.

Gravemann U, Volland J, Nau H.

Neurotoxicol Teratol. 2008 Sep-Oct;30(5):390-4. doi: 10.1016/j.ntt.2008.03.060. Epub 2008 Mar 19.

PMID:
18455366
10.
11.

Benzodiazepine amplification of valproate teratogenic effects in children of mothers with absence epilepsy.

Laegreid L, Kyllerman M, Hedner T, Hagberg B, Viggedahl G.

Neuropediatrics. 1993 Apr;24(2):88-92.

PMID:
7687042
12.

Pregnancy and the risk of teratogenicity.

Lindhout D, Omtzigt JG.

Epilepsia. 1992;33 Suppl 4:S41-8. Review.

PMID:
1425493
13.

Valproic acid-induced alterations in growth and neurotrophic factor gene expression in murine embryos [corrected].

Bennett GD, Wlodarczyk B, Calvin JA, Craig JC, Finnell RH.

Reprod Toxicol. 2000 Jan-Feb;14(1):1-11. Erratum in: Reprod Toxicol 2000 Mar-Apr;14(2):181.

PMID:
10689198
14.

Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes.

Kini U, Adab N, Vinten J, Fryer A, Clayton-Smith J; Liverpool and Manchester Neurodevelopmental Study Group.

Arch Dis Child Fetal Neonatal Ed. 2006 Mar;91(2):F90-5. Epub 2005 Oct 20.

15.

Predicting the human teratogenic potential of the anticonvulsant, valproic acid, from a non-human primate model.

Mast TJ, Cukierski MA, Nau H, Hendrickx AG.

Toxicology. 1986 May;39(2):111-9.

PMID:
3085290
16.

Developmental neurotoxicity of anticonvulsants: human and animal evidence on phenytoin.

Adams J, Vorhees CV, Middaugh LD.

Neurotoxicol Teratol. 1990 May-Jun;12(3):203-14. Review.

PMID:
2196420
17.

Valproate-induced neural tube defects in folate-binding protein-2 (Folbp2) knockout mice.

Spiegelstein O, Merriweather MY, Wicker NJ, Finnell RH.

Birth Defects Res A Clin Mol Teratol. 2003 Dec;67(12):974-8.

PMID:
14745917
19.

Supplemental Content

Support Center